THC Farmaceuticals, Inc. (CBDG)
USD 0.01
(8.0%)
USD 0.01
(8.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.95 Thousand USD | -252.75% |
| 2022 | -8491.00 USD | 52.32% |
| 2021 | -17.81 Thousand USD | 45.54% |
| 2020 | -32.7 Thousand USD | 79.32% |
| 2019 | -158.09 Thousand USD | -937.34% |
| 2018 | -15.24 Thousand USD | -108.77% |
| 2017 | -7300.00 USD | 94.64% |
| 2016 | -136.12 Thousand USD | 0.0% |
| 2014 | -24.02 USD | -22.63% |
| 2013 | -19.59 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 Q3 | -6320.00 USD | 43.97% |
| 2022 Q1 | -1690.00 USD | 0.0% |
| 2022 Q2 | -11.28 Thousand USD | -567.46% |
| 2021 FY | -17.81 Thousand USD | 45.54% |
| 2020 FY | -32.7 Thousand USD | 79.32% |
| 2020 Q1 | -9680.00 USD | 0.0% |
| 2019 Q3 | -49.05 Thousand USD | -17.43% |
| 2019 FY | -158.09 Thousand USD | -937.34% |
| 2019 Q2 | -41.77 Thousand USD | 0.0% |
| 2018 FY | -15.24 Thousand USD | -108.77% |
| 2017 FY | -7300.00 USD | 94.64% |
| 2016 FY | -136.12 Thousand USD | 0.0% |
| 2015 Q2 | -19.53 USD | -129.35% |
| 2015 Q1 | -8.51 USD | -25.97% |
| 2015 Q3 | -35.39 USD | -81.22% |
| 2014 Q2 | -2.01 USD | 84.29% |
| 2014 Q1 | -12.77 USD | -302.81% |
| 2014 FY | -24.02 USD | -22.63% |
| 2014 Q4 | -6.76 USD | -171.77% |
| 2014 Q3 | -2.49 USD | -23.98% |
| 2013 FY | -19.59 USD | 0.0% |
| 2013 Q2 | -1.59 USD | 0.0% |
| 2013 Q3 | -4.05 USD | -154.27% |
| 2013 Q4 | -3.17 USD | 21.81% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 97.757% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 99.406% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.832% |
| Nascent Biotech, Inc. | -2.22 Million USD | 98.657% |
| Rebus Holdings, Inc. | -664 Thousand USD | 95.489% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.037% |
| Qrons Inc. | -643.67 Thousand USD | 95.347% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 92.312% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.946% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 92.791% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.781% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.958% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.609% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 88.556% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.96% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 98.949% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 98.05% |
| Mesoblast Limited | -84.14 Million USD | 99.964% |
| Marizyme, Inc. | -34.08 Million USD | 99.912% |
| Genus plc | 6.4 Million USD | 100.468% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.307% |
| Pharming Group N.V. | -4.87 Million USD | 99.386% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 98.492% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 96.784% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.641% |
| ContraFect Corporation | -56.88 Million USD | 99.947% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 99.342% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 97.864% |
| IMV Inc. | -38.67 Million USD | 99.923% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 98.911% |
| MultiCell Technologies, Inc. | -722.81 USD | -4043.828% |
| ONE Bio Corp. | 13.68 Million USD | 100.219% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.201% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.949% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 93.8% |
| Q BioMed Inc. | -3.44 Million USD | 99.131% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.846% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 98.86% |
| Biomind Labs Inc. | -1 Million USD | 97.033% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.946% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 98.968% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 99.549% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 98.393% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.811% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 98.45% |
| GB Sciences, Inc. | -1.42 Million USD | 97.891% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.691% |
| HST Global, Inc. | -140.9 Thousand USD | 78.743% |
| CSL Limited | 3.7 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 97.337% |
| Halberd Corporation | -75.05 Thousand USD | 60.091% |
| Enzolytics Inc. | -2.14 Million USD | 98.606% |
| Agentix Corp. | -1.37 Million USD | 97.817% |
| Resverlogix Corp. | -12.74 Million USD | 99.765% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 99.055% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.993% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 97.131% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 98.974% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 98.104% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 99.12% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.448% |
| Zenith Capital Corp. | -8.94 Million USD | 99.665% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.993% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -71.93% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 98.78% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 82.536% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 98.506% |
| Kadimastem Ltd | -3.04 Million USD | 99.015% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 96.956% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 97.615% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.615% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 83.496% |
| LadRx Corporation | -3.82 Million USD | 99.217% |
| Cell Source, Inc. | -4.32 Million USD | 99.308% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 95.64% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 95.64% |
| NovAccess Global Inc. | -2.46 Million USD | 98.786% |
| Affymax, Inc. | -15.04 Million USD | 99.801% |
| Itoco Inc. | -919.14 Thousand USD | 96.741% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 99.293% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 97.323% |
| Mobile Lads Corp. | -554.55 Thousand USD | 94.599% |
| CytoDyn Inc. | -18.05 Million USD | 99.834% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -18.999% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 86.39% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 94.696% |
| SYBLEU INC | -149.18 Thousand USD | 79.922% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 98.351% |
| International Stem Cell Corporation | -663 Thousand USD | 95.482% |
| Bioxytran, Inc. | -3.82 Million USD | 99.216% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 43.1% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -47.257% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.917% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 98.149% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 95.93% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 99.037% |
| Neutra Corp. | -229.48 Thousand USD | 86.948% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.829% |
| PureTech Health plc | -146.19 Million USD | 99.98% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.861% |
| IXICO plc | -1.43 Million USD | 97.916% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.684% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.975% |
| CSL Limited | 3.81 Billion USD | 100.001% |
| Cellectis S.A. | -108.85 Million USD | 99.972% |